mDC3 vaccine

The mDC3 vaccine is an autologous, mature dendritic cell-based immunotherapy developed by the University of Pennsylvania, specifically investigated for the treatment of resected hypermutated colorectal cancer. The vaccine is produced by harvesting a patient's own monocytes via leukapheresis, differentiating them into dendritic cells, and maturing them using a specific "mDC3" cocktail—typically involving interferon-gamma and Toll-like receptor (TLR) agonists. This maturation process is designed to optimize the cells' production of interleukin-12 (IL-12p70) and enhance their ability to prime Type 1 T-cell (Th1) and cytotoxic T-lymphocyte (CTL) responses. In patients with hypermutated colorectal cancer (often characterized by high microsatellite instability and a high neoantigen burden), the vaccine aims to stimulate a robust immune response against residual tumor cells to prevent disease recurrence following surgical resection.

Other names

Mature Dendritic Cell VaccineUPenn mDC3 vaccinemDC3 Dendritic Cell VaccinemDC-3 Dendritic Cell VaccinemDC 3 Dendritic Cell Vaccine